Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-27
2005-09-27
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S866000
Reexamination Certificate
active
06949555
ABSTRACT:
The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of excessive cardiovascular morbidity (eg, myocardial infarction, arterial occlusive disease, atherosclerosis and stroke) and cardiovascular mortality, prevention of cancer and reduction of cancer deaths. Additionally, the invention relates to the use of a treatment for diseases and conditions that are associated with IGM, IGT or IFG.
REFERENCES:
patent: WO 98/56378 (1998-12-01), None
patent: WO 00/27434 (2000-05-01), None
patent: WO 00/28989 (2000-05-01), None
Li et al., “Effect of metformin on impaired glucose tolerance (IGT) patients”, Jiefangjun Yixue Zazhi (1999), 24(2), pp. 107-109 (see the enclosed abstract).
Derwent Abstract 2000-03788, Dunning et al., “Nateglinide improves prandial glucose excursions by restoring early insulin secretion in pre-diabetic monkeys” (XP-002148734).
Derwent Abstract PREV 199900368837, Dunning et al. Mimicking cephalic insulin release with the rapid onset/short duratio insulinotrophic agent, nateglinide, reduces prandial glucose excursions without increasing total insulin exposure in IGT monkeys. (XP-002148735).
Sartor et al., Diabetes, vol. 29, pp. 41-49 (1980) (XP-000938566).
Page et al., Quarterly Journal of Medicine, vol. 86, pp. 145-154 (1993) (XP-000938433).
Melander, A. , Diabetic Medicine, vol. 13, pp. 143-147 (1996) (XP-000938428.
International Search Report.
Emmons Rebecca
Guitard Christiane
Müller Beate
Ferraro Gregory D.
Novartis AG
Weddington Kevin E.
LandOfFree
Use of organic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of organic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of organic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3395186